Renga Pakeeree, MD
Psychiatry · Stow, OHNPI 1285671537
Payments from drug & device makers
Across 1,053 payments — averaging $128.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$91K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$16K
- Idorsia Pharmaceuticals US Inc$8K
- E.r. Squibb & Sons, L.L.C.$8K
- Teva Pharmaceuticals USA, Inc.$2K
- Neurocrine Biosciences, Inc.$2K
- plus $9K from 21 others
Across 3 payments — averaging $1333.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Acadia Pharmaceuticals Inc$4K
What the payments were for
- Consulting fees$11,0208%
- Speaking & faculty fees$93,36369%
- Travel & lodging$7,8496%
- Food & beverage$22,62117%
- Education$7221%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 372 | $91,494 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 113 | $15,678 |
| Idorsia Pharmaceuticals US Inc | 12 | $7,806 |
| E.r. Squibb & Sons, L.L.C. | 48 | $7,536 |
| Teva Pharmaceuticals USA, Inc. | 68 | $2,324 |
| Neurocrine Biosciences, Inc. | 70 | $1,704 |
| Otsuka America Pharmaceutical, Inc. | 56 | $1,554 |
| Alkermes, Inc. | 57 | $1,339 |
| Johnson & Johnson | 32 | $1,277 |
| Axsome Therapeutics, Inc. | 34 | $1,241 |
| Vanda Pharmaceuticals Inc. | 54 | $1,007 |
| Acadia Pharmaceuticals Inc | 49 | $811 |
| Lundbeck LLC | 41 | $757 |
| Sunovion Pharmaceuticals Inc. | 11 | $171 |
| Avanir Pharmaceuticals, Inc. | 11 | $159 |
| Supernus Pharmaceuticals, Inc. | 1 | $125 |
| Lilly USA, LLC | 1 | $122 |
| Almatica Pharma LLC | 5 | $105 |
| Eisai Inc. | 4 | $93 |
| Merck | 5 | $87 |
| Bausch Health US, LLC | 3 | $57 |
| TMS Neurohealth Centers Inc. | 1 | $29 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $25 |
| Noven Therapeutics, LLC | 1 | $22 |
| Alfasigma USA, Inc. | 1 | $22 |
| Noven Pharmaceuticals, Inc. | 1 | $15 |
| Neuronetics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$135,574 in reported general payments places this provider in the 95th percentile of 1,119 psychiatry providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 41 | $280,829 |
| Austedo XrDeutetrabenazine | 41 | $172,276 |
| VraylarCariprazine Hcl | 111 | $140,583 |
| NuplazidPimavanserin Tartrate | 16 | $75,930 |
| Invega SustennaPaliperidone Palmitate | 17 | $43,429 |
| LybalviOlanzapine/Samidorphan Malate | 13 | $21,041 |
| CobenfyXanomeline Tart/Trospium Chlor | 20 | $15,430 |
| RexultiBrexpiprazole | 16 | $12,160 |
| Clozapine | 282 | $11,656 |
| LexaproEscitalopram Oxalate | 12 | $7,540 |
| NamzaricMemantine Hcl/Donepezil Hcl | 12 | $6,962 |
| Paliperidone ErPaliperidone | 25 | $6,191 |
| Quetiapine Fumarate | 277 | $5,810 |
| Perphenazine | 25 | $4,329 |
| Divalproex Sodium | 88 | $4,134 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,704 | $280,82941 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $2,324 | $172,27641 claims |
| AbbVieVraylar, Lexapro, Namzaric | $91,494 | $155,085135 claims |
| Acadia Pharmaceuticals IncNuplazid | $811 | $75,93016 claims |
| Johnson & JohnsonInvega Sustenna | $1,277 | $43,42917 claims |
| Alkermes, Inc.Lybalvi | $1,339 | $21,04113 claims |
| E.r. Squibb & Sons, L.L.C.Cobenfy | $7,536 | $15,43020 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,554 | $12,16016 claims |
| Lilly USA, LLCOlanzapine | $122 | $3,826144 claims |
| Almatica Pharma LLCSertraline Hcl | $105 | $1,01972 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,119 psychiatry providers in Ohio.
Other psychiatry in Stow
- Shishuka MalhotraCanton$15M
- Henry NasrallahCincinnati$3.8M
- Otto DuenoDayton$3.1M
- Diab AlmhanaAvon Lake$2.7M
- Mohamed Abdel AzizWest Chester$2.6M
- Fred RomeoColumbus$2.3M
- Mark WoyshvilleMiddleburg Heights$2.2M
- Amita PatelDayton$2.1M
- Caleb AdlerCincinnati$2M
- Richard SandersDayton$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.